Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R S Belder

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2026
Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's diseaseChristopher R S Belder, Nick C Fox
The Lancet. Neurology|July 18, 2023
Preparing for disease-modifying therapies in Alzheimer's diseaseChristopher R S Belder, Jonathan M Schott, Nick C Fox
Frontiers in Neurology|January 26, 2023
The problematic syndrome of right temporal lobe atrophy: Unweaving the phenotypic rainbowChristopher R S Belder, Anthipa Chokesuwattanaskul, Charles R Marshall, et al.
The Lancet. Neurology|September 20, 2024
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophyChristopher R S Belder, Delphine Boche, James A R Nicoll, et al.
The Lancet. Neurology|February 22, 2025
Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority - Authors' replyChristopher R S Belder, Delphine Boche, James A R Nicoll, et al.
Practical Neurology|September 17, 2024
Genetic testing in dementiaAntoinette O'Connor, Natalie S Ryan, Christopher R S Belder, et al.
Journal of Neurology|October 31, 2023
Primary progressive aphasia: six questions in search of an answerChristopher R S Belder, Charles R Marshall, Jessica Jiang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 2, 2024
The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestationsCharles Arber, Christopher R S Belder, Filip Tomczuk, et al.
Brain Communications|April 23, 2026
Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer's diseaseIsaac Llorente-Saguer, Rebecca Gabriele, Teisha Y Bradshaw, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timingChristopher R S Belder, Amanda J Heslegrave, Owen Swann, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2026
Comparing amyloid immunotherapy with cholinesterase inhibitors for Alzheimer's diseaseChristopher R S Belder, Nick C Fox
The Lancet. Neurology|July 18, 2023
Preparing for disease-modifying therapies in Alzheimer's diseaseChristopher R S Belder, Jonathan M Schott, Nick C Fox
Frontiers in Neurology|January 26, 2023
The problematic syndrome of right temporal lobe atrophy: Unweaving the phenotypic rainbowChristopher R S Belder, Anthipa Chokesuwattanaskul, Charles R Marshall, et al.
The Lancet. Neurology|September 20, 2024
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophyChristopher R S Belder, Delphine Boche, James A R Nicoll, et al.
The Lancet. Neurology|February 22, 2025
Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority - Authors' replyChristopher R S Belder, Delphine Boche, James A R Nicoll, et al.
Practical Neurology|September 17, 2024
Genetic testing in dementiaAntoinette O'Connor, Natalie S Ryan, Christopher R S Belder, et al.
Journal of Neurology|October 31, 2023
Primary progressive aphasia: six questions in search of an answerChristopher R S Belder, Charles R Marshall, Jessica Jiang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 2, 2024
The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestationsCharles Arber, Christopher R S Belder, Filip Tomczuk, et al.
Brain Communications|April 23, 2026
Unbiased data-driven analysis of five amyloid-beta peptides for biomarker investigations in familial Alzheimer's diseaseIsaac Llorente-Saguer, Rebecca Gabriele, Teisha Y Bradshaw, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timingChristopher R S Belder, Amanda J Heslegrave, Owen Swann, et al.
Pageof 2